Cargando…
Determination of Oseltamivir in Human Plasma by HPLC-MS/MS
A procedure for the determination of oseltamivir in human plasma by high-performance liquid chromatography( tandem mass spectrometry (HPLC-MS/MS) was proposed and validated. Arapid and easy-to-use method of liquid(liquid extraction with ethyl acetate using venlafaxine as an internal standard was use...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105356/ https://www.ncbi.nlm.nih.gov/pubmed/37152765 http://dx.doi.org/10.1007/s11094-023-02858-5 |
_version_ | 1785026193466064896 |
---|---|
author | Lakeev, A. P. Abdrashitova, N. Yu. Bryushinina, O. S. Frelikh, G. A. Tsuran, D. V. Zyuz’kova, Yu. G. Udut, V. V. |
author_facet | Lakeev, A. P. Abdrashitova, N. Yu. Bryushinina, O. S. Frelikh, G. A. Tsuran, D. V. Zyuz’kova, Yu. G. Udut, V. V. |
author_sort | Lakeev, A. P. |
collection | PubMed |
description | A procedure for the determination of oseltamivir in human plasma by high-performance liquid chromatography( tandem mass spectrometry (HPLC-MS/MS) was proposed and validated. Arapid and easy-to-use method of liquid(liquid extraction with ethyl acetate using venlafaxine as an internal standard was used during sample preparation. The addition of benzoic acid to aqueous acetonitrile solutions of the analyte was shown to prevent its oxidative degradation. The detection limit and limit of quantitation were 0.08 and 0.30 ng/mL, respectively; the calibration range, 0.3-200 ng/mL (R(2) = 0.9937); the total analysis time, 3.2 min. The within- and between-run accuracy ranged from 97 to 105%. The precision was <10%. The proposed procedure was characterized by selective determination of the analyte, the absence of significant matrix effects, the ability to dilute samples with high analyte concentrations, and satisfactory extraction recovery (≥89%). The analyte was stable when stored in plasma samples (4 h at room temperature, 31 d at (80°C, after three freeze(thaw cycles) and extracts under autosampler storage conditions (24 h at 15°C). The procedure was successfully used for oseltamivir quantitation in actual plasma samples from healthy volunteers obtained during a bioequivalence study of the new generic drug. |
format | Online Article Text |
id | pubmed-10105356 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-101053562023-04-17 Determination of Oseltamivir in Human Plasma by HPLC-MS/MS Lakeev, A. P. Abdrashitova, N. Yu. Bryushinina, O. S. Frelikh, G. A. Tsuran, D. V. Zyuz’kova, Yu. G. Udut, V. V. Pharm Chem J Structure of Chemical Compounds, Methods of Analysis and Process Control A procedure for the determination of oseltamivir in human plasma by high-performance liquid chromatography( tandem mass spectrometry (HPLC-MS/MS) was proposed and validated. Arapid and easy-to-use method of liquid(liquid extraction with ethyl acetate using venlafaxine as an internal standard was used during sample preparation. The addition of benzoic acid to aqueous acetonitrile solutions of the analyte was shown to prevent its oxidative degradation. The detection limit and limit of quantitation were 0.08 and 0.30 ng/mL, respectively; the calibration range, 0.3-200 ng/mL (R(2) = 0.9937); the total analysis time, 3.2 min. The within- and between-run accuracy ranged from 97 to 105%. The precision was <10%. The proposed procedure was characterized by selective determination of the analyte, the absence of significant matrix effects, the ability to dilute samples with high analyte concentrations, and satisfactory extraction recovery (≥89%). The analyte was stable when stored in plasma samples (4 h at room temperature, 31 d at (80°C, after three freeze(thaw cycles) and extracts under autosampler storage conditions (24 h at 15°C). The procedure was successfully used for oseltamivir quantitation in actual plasma samples from healthy volunteers obtained during a bioequivalence study of the new generic drug. Springer US 2023-04-15 2023 /pmc/articles/PMC10105356/ /pubmed/37152765 http://dx.doi.org/10.1007/s11094-023-02858-5 Text en © Springer Science+Business Media, LLC, part of Springer Nature 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Structure of Chemical Compounds, Methods of Analysis and Process Control Lakeev, A. P. Abdrashitova, N. Yu. Bryushinina, O. S. Frelikh, G. A. Tsuran, D. V. Zyuz’kova, Yu. G. Udut, V. V. Determination of Oseltamivir in Human Plasma by HPLC-MS/MS |
title | Determination of Oseltamivir in Human Plasma by HPLC-MS/MS |
title_full | Determination of Oseltamivir in Human Plasma by HPLC-MS/MS |
title_fullStr | Determination of Oseltamivir in Human Plasma by HPLC-MS/MS |
title_full_unstemmed | Determination of Oseltamivir in Human Plasma by HPLC-MS/MS |
title_short | Determination of Oseltamivir in Human Plasma by HPLC-MS/MS |
title_sort | determination of oseltamivir in human plasma by hplc-ms/ms |
topic | Structure of Chemical Compounds, Methods of Analysis and Process Control |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105356/ https://www.ncbi.nlm.nih.gov/pubmed/37152765 http://dx.doi.org/10.1007/s11094-023-02858-5 |
work_keys_str_mv | AT lakeevap determinationofoseltamivirinhumanplasmabyhplcmsms AT abdrashitovanyu determinationofoseltamivirinhumanplasmabyhplcmsms AT bryushininaos determinationofoseltamivirinhumanplasmabyhplcmsms AT frelikhga determinationofoseltamivirinhumanplasmabyhplcmsms AT tsurandv determinationofoseltamivirinhumanplasmabyhplcmsms AT zyuzkovayug determinationofoseltamivirinhumanplasmabyhplcmsms AT udutvv determinationofoseltamivirinhumanplasmabyhplcmsms |